🇺🇸 FDA
Pipeline program

Coagulation Factor VIIa variant

MAA-201

Phase 2 mab completed

Quick answer

Coagulation Factor VIIa variant for Hemophilia A With Inhibitor is a Phase 2 program (mab) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CATALYST PHARMACEUTICALS, INC.
Indication
Hemophilia A With Inhibitor
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials